The study retrospectively reviewed every patient who underwent ablation of a biopsy-proven T1 renal cell carcinoma at the center between March 2013 and June 2023. In total, 50 ablation procedures were performed on 46 tumors in 45 patients, with a mean tumor diameter of just 2.6 centimeters. The patients were not a healthy bunch: the mean age was 70 years, ranging from 45 to 85, and the average Charlson Comorbidity Index score was 5.5, a figure that corresponds to an estimated ten-year survival of only about 21 percent. In other words, these were precisely the patients for whom major surgery carries prohibitive risk, and yet their cancer outcomes matched or exceeded those reported in surgical series.

The technical machinery behind the results is worth unpacking. Radiofrequency ablation, the workhorse of the series, uses an internally cooled 17-gauge cluster electrode perfused with chilled saline at 70 milliliters per minute, tipped with a 2.5-centimeter active segment. The device runs a 12-minute impedance-controlled program, delivering alternating current that causes ionic agitation and resistive heating in the surrounding tissue, cooking tumor cells to destruction. The number of probe placements was scaled to tumor size, and the goal was a circumferential 0.5-centimeter margin of treated tissue around the tumor, a buffer designed to catch any microscopic extension beyond the visible mass.

Microwave ablation, introduced at the center in 2018, works differently. A 14-gauge antenna emits electromagnetic waves at 2450 megahertz, causing water molecules throughout the field to oscillate and generate frictional heat directly, rather than relying on conduction from the probe. That allows higher temperatures, larger ablation zones, and shorter treatment times, with power settings of 40, 60 or 100 watts and exposure times of 5, 10 or 15 minutes adapted to the tumor dimensions measured on pre-procedural CT. Cryotherapy, used in only a single case here, employs a 14-gauge cryoprobe and two freeze-thaw cycles to kill cells through ice-crystal formation, with the advantage of real-time monitoring of the ice ball during the procedure. Notably, if a tumor sat within 1.5 centimeters of the ureter, the team chose cryoablation, since thermal energy near the collecting system risks injuring this delicate structure.

Almost all procedures, 49 of 50, were performed under general anesthesia with combined CT and ultrasound targeting by one of three fellowship-trained interventional radiologists with five to eight years of ablation experience. Technical success, meaning satisfactory completion of the planned treatment protocol, was achieved in 100 percent of cases. Primary efficacy, defined as complete eradication of the tumor on the first follow-up CT or MRI, was 94 percent: 43 of 46 tumors. Median hospital stay was a single day, and follow-up imaging with multiphasic CT or contrast-enhanced MRI was performed at 3, 6, 9 and 12 months and then annually.

The survival statistics are the headline numbers. Overall survival was 97.4 percent at one year and 88.5 percent at both three and five years. Local tumor progression-free survival stood at 100 percent at one year and 95.2 percent at three and five years. Most strikingly, cancer-specific survival at five years was 100 percent: not a single patient in the cohort died of kidney cancer. The three deaths recorded during follow-up, from COVID-19 pneumonitis, cerebrovascular accident and decompensated liver disease at 4, 29 and 31 months respectively, were all unrelated to the malignancy. Kidney function was also preserved, with no statistically significant change in serum creatinine between the pre-procedure and one-month post-procedure measurements, a critical point given that many of these patients had limited renal reserve to begin with.

Complications occurred after 8 percent of procedures, four of 50, and all four followed radiofrequency ablation. One patient developed a pneumothorax during the procedure requiring chest drain insertion; another suffered a hemothorax, also managed with a chest drain, which prolonged the hospital stay to 13 days. A third developed a perinephric collection three months after ablation, causing mild hydronephrosis that was treated with image-guided drainage and antibiotics. The fourth experienced acute urinary retention, likely related to general anesthesia, resolved with a catheter that was successfully removed 48 hours later. That complication profile compares favorably with the published literature: a systematic review covering 2,258 thermal ablations reported an overall complication rate of 16 percent and a major complication rate of 3 percent.

Perhaps the most provocative finding is the head-to-head comparison between the two heat-based modalities. Radiofrequency ablation achieved primary efficacy in 100 percent of its 28 tumors, while microwave ablation succeeded in only 82 percent of its 17, a statistically significant difference. The failure pattern was telling: tumors in which microwave ablation failed were significantly larger, with a median diameter of 3.8 centimeters versus 2.4 centimeters for those successfully treated. Only three of the 17 microwave patients failed primary treatment, so the numbers are small, but the result aligns with a well-established inverse relationship between tumor size and ablation success. Other groups have reached similar conclusions, with one study reporting that increasing tumor size more than doubled the hazard of primary efficacy failure, and another finding residual tumor rates of 5.6 percent for T1a tumors versus 19.1 percent for larger T1b lesions.

The authors, however, urge caution in interpreting the radiofrequency-versus-microwave gap. Microwave ablation was adopted at the center only in 2018, and the technology arrived with a steep learning curve. Manufacturers marketed microwave systems as less susceptible to the heat-sink effect, in which flowing blood near large vessels carries heat away from the ablation zone, and as capable of treating larger tumors faster with a single antenna. But at the time of introduction, there were no in-vivo treatment charts for the kidney; radiologists had to plan therapy using ablation measurements made on ex-vivo animal liver. Compounding the problem, the microwave antenna produces a non-spherical ablation zone that behaves differently from radiofrequency and cryotherapy probes: the distal treatment margin sits proximal to the antenna tip, whereas with radiofrequency and cryoablation the zone extends beyond the electrode tip. Misjudging that geometry, even slightly, can leave residual viable tumor at the margin, and two of the three failures in this series involved endophytic tumors abutting the collecting system, an anatomically demanding location.

The broader context matters too. Guidelines from the European Association of Urology and the American Urological Association still recommend partial nephrectomy as first-line treatment for T1 renal cell carcinoma, citing a lack of high-level evidence for ablation. But every comparison between ablation and surgery is confounded by selection bias: surgical series enroll younger, healthier patients, while ablation is disproportionately offered to the elderly and comorbid. A large retrospective comparison of 1,057 partial nephrectomies against 180 radiofrequency and 187 cryoablation cases found the surgical patients were significantly younger and healthier. Against that backdrop, the Dublin results, 100 percent technical success, 94 percent primary efficacy, 95 percent five-year local control and zero cancer deaths in a cohort averaging age 70 with heavy comorbidity, are difficult to dismiss. The study has the usual limitations of a small, single-center, retrospective design, and only six patients were followed to five years. Still, as imaging picks up ever more small, asymptomatic kidney tumors on incidental CT scans, the case for a needle-based treatment that sends patients home the next day, with their kidneys and their cancer prognosis intact, is becoming steadily harder to ignore.

Subject of Research: Image-guided thermal ablation outcomes for T1 renal cell carcinoma over ten years

Article Title: Image guided energy-based ablation of T1 renal cell cancer: a ten-year single centre experience

Article References: Ryan, J. P. C., Lynch, O. E., McGuire, B. B., & Cantwell, C. P. (2025). Image guided energy-based ablation of T1 renal cell cancer: a ten-year single centre experience. CVIR Oncology, 1(1), Article 2. https://doi.org/10.1007/s44343-025-00001-7

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00001-7

Keywords: renal cell carcinoma, tumor ablation, radiofrequency ablation, microwave ablation, cryotherapy, interventional radiology, kidney cancer, T1 tumors, overall survival, cancer-specific survival, nephron-sparing therapy, CT-guided procedures

The study, published as a short communication in CVIR Oncology, analyzed isotherm charts from three FDA-certified cryoablation systems: two argon-based Joule–Thomson platforms, Boston Scientific’s System A and Endocare/Varian’s System B, and a liquid nitrogen system, IceCure Medical’s System C. All measurements had been performed in ultrasonic gels under standardized conditions, with 216 data points covering single needles and clustered needle configurations. The authors defined the LIR as the width of the −20 °C or −40 °C isotherm divided by the width of the visible ice ball, expressed as a percentage. A higher ratio means a larger share of the frozen zone is cold enough to guarantee cell death.

The physics behind the metric is rooted in how cells die under extreme cold. Below −40 °C, intracellular ice crystals form and physically shred cellular structures, triggering immediate necrosis. At temperatures as high as −20 °C, secondary mechanisms come into play, including osmotic stress and ischemic injury that starve tissue of blood supply. Because these lethal zones cannot be seen during a procedure, operators currently rely on the visible ice ball diameter and probe spacing as proxies, a practice the authors argue leaves a dangerous margin of uncertainty that can lead to inadequate tumor coverage and local recurrence.

The results were striking. Across all systems, isotherm widths correlated strongly and linearly with ice ball size, with correlation coefficients ranging from 0.880 to 0.999. But the proportion of lethal territory within the ice ball differed dramatically by technology. The liquid nitrogen System C achieved the highest ratios, with the −20 °C isotherm spanning 80.6 percent of the ice ball on average and the −40 °C isotherm covering 60.3 percent. The argon-based Systems A and B trailed significantly, both reaching about 69.6 percent at −20 °C, while their −40 °C ratios fell to 44 percent and 51.4 percent respectively, differences the authors report as statistically significant.

The explanation lies in the cooling technologies themselves. Joule–Thomson systems drop their temperature by expanding high-pressure argon gas, at 3200 PSI, through a throttling orifice, a process that supports multiple cryoprobes working in parallel. Liquid nitrogen systems operate at far lower pressures, around 100 PSI, but reach colder temperatures faster. The trade-off, the study notes, is that liquid nitrogen systems may struggle with very large ice balls, where peripheral warming erodes the lethal core, while clustered cryoprobes enhance energy removal but demand more complex insertion techniques.

That trade-off produced the study’s most clinically actionable finding: a threshold effect at roughly 45 millimeters. Linear regression analysis showed that for ice balls smaller than about 45 mm in width, a single liquid nitrogen needle delivers larger lethal isotherms than any single argon needle. Beyond that threshold, the regression lines intersect and the picture reverses: clusters of Joule–Thomson needles produce bigger lethal zones, with an almost perfect correlation of 0.998 to 0.999. Notably, when System A’s needles were clustered, their LIRs rose to 79.3 percent at −20 °C and 60.9 percent at −40 °C, statistically indistinguishable from the liquid nitrogen system’s single-needle performance.

For interventional radiologists, the implications could reshape device selection and preoperative planning. If a tumor is expected to generate an ice ball under 45 mm, the data suggest a single liquid nitrogen probe may be the more efficient choice. For larger targets, clustered argon probes offer superior coverage. Because the LIR quantifies the relationship between what is visible on screen and the effective ablation zone, it could allow operators to estimate the required number of probes and their optimal spacing before the first incision, potentially shortening procedures and reducing complications. The finding that the −20 °C isotherm can encompass up to 80 percent of the ice ball even hints that real-time thermometry might become unnecessary if LIR values reliably predict ablation zones.

The metric also fills a gap in how the field compares competing technologies. Until now, manufacturers’ claims rested on raw ice ball dimensions and probe spacing, figures that say nothing about the lethal fraction of the frozen volume. By normalizing lethal isotherm widths to the visible freezing front, the LIR offers a common currency for benchmarking cryoprobes, needle gauges, and chamber lengths across vendors. The authors suggest it could become a standardized yardstick for regulators, buyers, and clinicians alike, in the same way that metrics like specific absorption rate structure comparisons in other energy-based therapies.

The study is not without caveats, and the authors are candid about them. All isotherm data came from ultrasonic gels, not living tissue. Biological tissue brings perfusion, heterogeneity, and variable thermal conductivity, all of which alter heat transfer in vivo and could shift LIR values in real patients. Testing conditions also varied somewhat between manufacturers, with ambient temperatures of 20 to 23 °C, probe depths of 2 to 3 cm, and freeze durations of 10 to 15 minutes, and although FDA certification imposed standardized protocols, cross-vendor methodological differences could introduce bias. The corresponding author has consulted for all three companies whose systems were analyzed, a potential conflict the authors state was mitigated through standardized data collection and analysis.

Future work, the team argues, should validate LIR against histologically confirmed ablation zones in animal and human tissue, run prospective trials comparing procedures planned with and without the metric, and build computational models that fold tissue-specific properties into the calculation. If those steps succeed, the Lethal Isotherm Ratio could transform a field that has long judged its instruments by the size of the ice they make rather than the death they deliver. For now, the message is clear: not all ice balls are created equal, and the difference between 44 percent and 80 percent lethal coverage may be the difference between a cured tumor and one that comes back.

Subject of Research: A standardized metric, the lethal isotherm ratio, for comparing cryoablation needles and systems based on lethal temperature zones within visible ice balls.

Article Title: Lethal isotherm ratio to standardize the comparison of cryoablation needles and systems

Article References: Cornelis, A. A., Bodard, S., & Cornelis, F. H. (2025). Lethal isotherm ratio to standardize the comparison of cryoablation needles and systems. CVIR Oncology, 1(1), Article 3. https://doi.org/10.1007/s44343-025-00004-4

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00004-4

Keywords: cryoablation, lethal isotherm ratio, cryoprobes, liquid nitrogen, Joule-Thomson, interventional radiology, tumor ablation, isotherms, ice ball, device comparison, oncology, Lethal

The technology in question is histotripsy, a non-invasive ablation method that uses precisely focused bursts of ultrasound energy to mechanically destroy tissue. Rather than burning tumors with heat, freezing them with cryogenic probes, or killing cells with electric fields, histotripsy generates controlled cavitation bubbles at the focal point of an ultrasound beam. These bubbles expand and collapse in microseconds, creating mechanical forces that fragment cells into subcellular debris. The body then processes this debris naturally, and because the technique is non-thermal, it spares surrounding structures such as blood vessels and bile ducts from the collateral damage that thermal methods can inflict. On paper, it sounds like everything a patient could want: no incisions, no radiation, and no heat.

Researchers led by Francois H. Cornelis, Rozan Bokhari, and Stephen B. Solomon of Memorial Sloan Kettering Cancer Center set out to quantify how public enthusiasm for histotripsy compares with its scientific foundation. They combined two complementary data streams spanning 2004 through 2025. To measure public interest, they extracted annual Search Volume Index values from Google Trends for six percutaneous ablation modalities: radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, pulsed electric field therapy, and histotripsy. To measure academic output, they counted yearly PubMed publications for each technique. They then applied formal statistical tools, using Mann-Kendall tests to determine whether trends were significant, Spearman rank correlation coefficients to measure how tightly public interest tracked academic output, and third-degree polynomial regression models to forecast trajectories through 2030.

The numbers are remarkable. Between 2020 and 2025, online searches for histotripsy increased by 31,100 percent, a rise so steep that the authors report a p-value below 0.001, meaning the probability of such a surge occurring by chance is vanishingly small. No other ablation technology comes close. Academic output grew as well, with PubMed publications on histotripsy rising 185.7 percent over the same period, a statistically significant increase. The forecasting models project that search interest will climb a further 350 percent and publications will rise 75 percent by 2030, with histotripsy and microwave ablation showing the strongest upward trajectories of all the modalities analyzed.

But the most revealing finding is not the magnitude of the surge. It is the order in which things happened. When the researchers computed Spearman correlation coefficients between public search interest and academic publications, histotripsy scored 0.79, the lowest of the modalities examined. Microwave ablation scored 0.83 and radiofrequency ablation 0.87, values indicating that for those established techniques, public attention rose roughly in step with the accumulating scientific literature. Histotripsy’s lower correlation captures an inversion of the classic sequence: public awareness exploded well before robust clinical evidence existed to support it. Geographic analysis reinforced how unusual this is. A Gini coefficient of 0.216, a measure of statistical dispersion where lower values indicate more even distribution, showed that interest in histotripsy is spread broadly across the country rather than concentrated in the academic medical centers where the research is actually being conducted.

The authors attribute this reversed pathway to vigorous commercial promotion combined with the technique’s inherent conceptual appeal. Early marketing has emphasized theoretical immunologic effects, the idea that destroying tumors mechanically might release antigens that stimulate a systemic anti-cancer immune response, along with broad claims of therapeutic potential. Yet regulatory clearance for histotripsy remains limited to narrow, ultrasound-guided liver indications. The gap between what is being promoted and what has been proven is where the authors see danger. Patients arrive at clinics with expectations shaped by promotional materials rather than peer-reviewed data, pressuring physicians to offer treatments that lack comprehensive validation. Hospitals, fearing competitive disadvantage, acquire expensive systems even when clinical need may not justify the investment. Resources flow toward technologies with limited demonstrated benefit while established treatments receive diminished attention.

This pattern has precedents, and they are cautionary ones. Irreversible electroporation, a technique that kills cells by permeabilizing their membranes with high-voltage electric pulses, experienced a similar wave of enthusiasm, rising quickly before plateauing as clinical trials revealed practical limitations. High-intensity focused ultrasound faced comparable challenges when its promise outpaced its reality. In both cases, the technology found legitimate but narrower roles than early advocates had claimed. The lesson, the authors argue, is that scientific rigor must be maintained even, and perhaps especially, when a technology’s potential seems extraordinary.

The current evidence base for histotripsy remains thin by the standards that typically govern adoption in oncology. Published studies are predominantly single-center experiences with limited follow-up periods. The purported immunologic effects, which feature prominently in promotional narratives, remain entirely theoretical in clinical application, even though related work on pulsed electric fields has shown time-dependent cytokine responses in preclinical liver ablation models and preclinical histotripsy studies have demonstrated encouraging safety profiles. None of this amounts to clinical proof that histotripsy triggers meaningful systemic anti-tumor immunity in patients. Meanwhile, patients seeking non-invasive options encounter marketing that the authors say overstates capabilities while minimizing limitations, raising ethical questions about informed consent and the fair allocation of healthcare resources. The pressure for rapid return on investment incentivizes application beyond established indications, which could compromise both patient safety and scientific integrity.

None of this diminishes histotripsy’s genuine promise, and the authors are careful to say so. Preclinical work demonstrates precise mechanical tissue destruction with encouraging safety, and the non-thermal mechanism offers theoretical advantages that merit serious investigation. The technology may ultimately transform minimally invasive oncology. But responsible development, they argue, requires prioritizing clinical validation over market expansion. Rigorous multicenter trials with standardized protocols must establish efficacy before promotional campaigns drive adoption. The interventional oncology community, in their framing, faces a defining moment: it can allow marketing momentum and investor enthusiasm to push premature integration, risking patient harm and professional credibility when outcomes fail to match promises, or it can channel the surge of public interest toward accelerated but methodologically sound validation, maintaining transparent communication about what the technology can and cannot yet do.

The broader significance of this study extends beyond a single technology. By quantifying the divergence between public interest and academic output, the researchers have provided a measurable indicator of a phenomenon that clinicians have long observed anecdotally: the internet age allows demand for a treatment to materialize before the evidence to justify it. Only through large, rigorous studies demonstrating durable clinical benefit, the authors conclude, can widespread histotripsy adoption serve patients rather than shareholders. Whether the field heeds that warning, or repeats the cycle of hype and disappointment that has caught previous technologies, will be one of the more consequential stories in cancer medicine over the coming decade.

Subject of Research: Public and academic interest trends in percutaneous tumor ablation technologies, focusing on histotripsy's atypical adoption pathway

Article Title: Public interest and academic trends in percutaneous ablations: histotripsy’s reversed innovation pathway

Article References: Cornelis, F. H., Bokhari, R., & Solomon, S. B. (2025). Public interest and academic trends in percutaneous ablations: histotripsy’s reversed innovation pathway. CVIR Oncology, 1(1), Article 14. https://doi.org/10.1007/s44343-025-00017-z

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00017-z

Keywords: histotripsy, percutaneous ablation, interventional oncology, Google Trends, PubMed, medical innovation, commercial promotion, clinical validation, ultrasound therapy, tumor ablation, irreversible electroporation, informed consent

The study, conducted by Laureen Fröhlich and Andreas H. Mahnken at Marburg University, distributed an anonymous 47-item online questionnaire to 300 fifth-year medical students taking regular radiology courses across two academic terms, between winter 2023 and summer 2024. Eighty-five students completed the survey, a response rate of 28.3 percent, with 67 percent female participants and a mean age of 24.9 years. The questionnaire, based on previously published survey instruments, covered demographic data, students’ knowledge of interventional radiology compared with other disciplines, their familiarity with specific procedures including oncologic, vascular and non-vascular interventions, and their understanding of the specialty’s clinical role. Students completed the survey without any prior teaching intervention, providing a genuine baseline of what five years of medical school had taught them. The study was approved by the institutional ethics committee.

The headline finding is a paradox of awareness without understanding. Every single participant, 100 percent, knew that interventional radiology exists alongside diagnostic radiology. But only 36.5 percent had any prior exposure to the field during their studies, and 67.1 percent rated their own knowledge of it as poor. Not a single student rated their knowledge as excellent, and only 4.7 percent considered it good. The gap between perceived and actual understanding was particularly revealing: 63.5 percent of students claimed to know which diseases interventional radiology could treat, and 58.8 percent said they were aware of the available procedures, yet when tested objectively on specific interventions, their performance collapsed. Only about a third, 35.7 percent, felt they knew when a patient should even be referred to the specialty.

The procedural knowledge test laid bare the blind spot. Students were presented with twelve exemplary interventional radiology procedures and correctly assigned only seven of them to the field. Vascular interventions fared well: 96.5 percent correctly identified arterial revascularization as an interventional radiology procedure, followed by percutaneous angioplasty at 92.9 percent, endovascular aortic repair at 88.2 percent, treatment of arterial bleeding at 84.5 percent and inferior vena cava filter implantation at 76.2 percent. But the oncologic procedures, the very heart of interventional oncology, were recognized far less often. Venous access port implantation for chemotherapy was correctly assigned by only 54.1 percent of students and hepatic artery infusion chemotherapy by 50.6 percent. Fewer than half correctly identified thermal ablation of renal tumors at 48.8 percent, hepatic tumor ablation at 43.5 percent or image-guided lung biopsy at 42.4 percent. Non-vascular procedures fared worst of all, with vertebroplasty recognized by a mere 20 percent of respondents.

The confusion extended beyond ignorance to outright misattribution. Of the five non-interventional-radiology procedures included as distractors, the majority of students failed to correctly exclude any of them. Removal of adrenal tumors and radiation therapy for bone metastases were correctly recognized as outside the field by only 45.8 percent and 42.4 percent of students respectively, while local treatment of rheumatoid arthritis and proton therapy for pancreatic tumors were correctly flagged by just 37.6 percent and 35.3 percent. In other words, many future physicians cannot reliably distinguish what interventional radiologists do from what surgeons, radiation oncologists or nuclear medicine specialists do, a deficit with real clinical consequences, since referring physicians who misunderstand a specialty’s therapeutic potential may delay or miss referrals and exclude minimally invasive, organ-sparing options from multidisciplinary treatment planning.

Students’ picture of the specialty’s clinical structure was similarly incomplete. On the positive side, 97.6 percent recognized that interventional radiology treats patients with serious illnesses, and around 96 percent acknowledged that it performs potentially life-saving interventions. But when asked about the organizational reality of modern practice, understanding wavered: 69 percent assumed interventional radiology departments run their own outpatient clinics, 65.5 percent believed they admit patients independently, and 64.3 percent thought they conduct ward rounds, while only 41.7 percent knew such departments may have their own inpatient beds. These structures are increasingly common as the specialty evolves from a procedural referral service into a fully clinical discipline responsible for the entire patient pathway, from initial consultation through admission, inpatient care, discharge and follow-up.

The career implications may be the most consequential finding of all. Although 70.6 percent of students expressed interest in interventional radiology, and 61.2 percent wanted to learn more about it, radiology as a career was decisively rejected. Not one student said they would definitely consider it, only 5.9 percent said rather yes, and 78.8 percent ruled it out as rather not or definitely not an option. The most cited reason, given by 57.6 percent, was too little patient contact, followed by too much work on the computer at 51.8 percent and simple lack of interest at 50.6 percent. The authors note that this perception of radiologists as isolated, screen-bound technicians is a widespread stereotype, reinforced by low exposure during training and by the shortage of interventional radiology-managed inpatient beds that limits bedside teaching. A European survey by the Cardiovascular and Interventional Radiological Society of Europe’s Trainee Forum found the same trend, with limited patient interaction the most cited deterrent.

This recruitment crisis arrives at precisely the wrong moment. Cancer remains one of the foremost causes of death worldwide, with 19.3 million new cases and nearly 10 million cancer-related deaths in 2020, and the global burden is projected to rise by 47 percent to approximately 28.4 million new cases annually by 2040. Meanwhile, a shortfall of around 10 million healthcare workers is anticipated by 2030, and shortages of clinical radiologists and interventional radiology specialists, worsened by aging, retirement and burnout, are particularly alarming because these specialties are critical for cancer diagnosis, staging and minimally invasive treatment. Crucially, unlike vascular interventions, which are often performed by other disciplines, interventional oncology procedures are carried out exclusively by interventional radiologists, meaning a shortage of incoming talent could directly limit the quality and accessibility of minimally invasive cancer therapy for years to come.

Part of the problem is structural. In the United States, interventional radiology has been recognized as a primary medical specialty since 2012, and the Integrated Interventional Radiology Residency introduced in 2016 established a structured six-year training pathway reflecting the discipline’s full clinical scope. In Europe, no standardized framework exists: in most countries, including Germany, interventional radiology holds no official subspecialty status and is instead embedded within radiology. It is entirely absent from Germany’s official national undergraduate medical curriculum. CIRSE has developed curricula, including an Interventional Radiology Curriculum for Medical Students that treats interventional oncology as a core area, but implementation of these non-mandatory frameworks remains inconsistent and dependent on local initiative. The result, the authors argue, is a self-perpetuating cycle in which invisibility in the curriculum breeds ignorance among students, ignorance deters career interest, and dwindling recruitment deepens the workforce shortage that keeps the specialty too stretched to teach.

Breaking that cycle, the researchers conclude, requires action on several fronts: establishing formal structural recognition of interventional radiology as a specialty or subspecialty, integrating it and interventional oncology into mandatory undergraduate modules, expanding teaching formats from lectures and symposia to bedside teaching and interdisciplinary case discussions, actively promoting the field as the clinical, patient-facing discipline it has become, and harmonizing training standards across Europe. The evidence suggests even modest interventions work, as short lectures and targeted teaching have been shown to improve student knowledge and career consideration. The authors acknowledge limitations, including the single-institution design, the 28.3 percent response rate that may have attracted students already interested in the field, and the use of predefined answer options that may have shaped responses about career objections. Still, the message is difficult to ignore: a field capable of burning away tumors through a pinhole cannot afford to remain, in the minds of the physicians who will soon refer patients to it, out of sight and out of mind.

Subject of Research: Medical students' knowledge and awareness of interventional oncology and interventional radiology in undergraduate medical education

Article Title: Out of sight, out of mind: interventional oncology’s underrepresentation in undergraduate medical education

Article References: Fröhlich, L., & Mahnken, A. H. (2025). Out of sight, out of mind: interventional oncology’s underrepresentation in undergraduate medical education. CVIR Oncology, 1(1), Article 23. https://doi.org/10.1007/s44343-025-00020-4

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00020-4

Keywords: interventional radiology, interventional oncology, medical education, undergraduate curriculum, cancer treatment, tumor ablation, medical students, workforce shortage, radiology career, Germany, survey study, minimally invasive therapy

The study, published in CVIR Oncology as an open-access short communication, enrolled 97 patients with primary or secondary liver malignancies, of whom 74 completed the final analysis. All participants were treated under conscious sedation with analgesia rather than general anesthesia, and all were interviewed systematically about their pain experience at three distinct time points: during catheter placement under CT fluoroscopy, at the time of radiation delivery when the catheters were removed, and later the same evening on the ward. Pain was scored on the standard numeric rating scale from zero, meaning no pain, to ten, meaning maximum pain. The researchers also tracked age, sex, the number of lesions and catheters, prior treatments, tumor volume, tumor location, and complications classified according to Society of Interventional Radiology guidelines.

The technical choreography of the procedure helps explain why the anesthesia question matters so much. Unlike thermal ablation, where a probe is inserted and the tumor is burned or frozen in a single session, CT-guided HDR brachytherapy unfolds in two stages separated by a change of location. First, under CT fluoroscopic guidance, the interventionalist percutaneously places brachytherapy applicators into and around the tumor while the patient receives intravenous midazolam and fentanyl alongside local lidocaine anesthesia at the puncture site. A second physician stands by throughout, monitoring vital signs and titrating medication. Once the catheters are positioned and the planning scan is complete, the puncture sites are sterilely covered and the patient is escorted to a dedicated radiation operating room, where the iridium-192 source delivers its dose. Only after irradiation are the catheters removed, creating a second moment of potential discomfort, and the patient is then observed for roughly an hour before transfer to the regular ward.

The pain data that emerged were strikingly reassuring. At catheter placement, the moment many clinicians would expect to hurt most, 74.5 percent of patients rated their pain as low, in the zero-to-two range, while 19.0 percent reported moderate pain and only 6.5 percent severe pain. At the time of radiation and catheter removal, the picture improved further: 84.0 percent reported low pain, 11.0 percent moderate, and 5.5 percent severe. On the ward afterward, 79.5 percent reported low pain, 16.0 percent moderate, and 4.0 percent severe. The median doses of sedation were modest, 112.5 micrograms of fentanyl and 2 milligrams of midazolam, underscoring how little pharmacological support the procedure actually demands when performed with careful local anesthesia and image guidance.

Two patterns within the data carry practical weight for clinicians. Women reported significantly higher pain at the time of irradiation, with a p-value below 0.001, and the number of treated lesions was associated with significantly higher pain levels at two of the three measured time points, with p below 0.05. No other parameter, including age, tumor volume, tumor location, or the number of prior treatments, showed a significant relationship with pain perception. The authors suggest that these findings point to patient groups, women and those with multiple lesions, who may warrant heightened attention and more aggressive pain management during brachytherapy, rather than a wholesale change in the sedation strategy.

Safety outcomes were equally encouraging. Across three months of follow-up, mild to moderate complications occurred in 23.0 percent of patients, consisting mainly of pain and fever, while no major complications were observed at all. Patient satisfaction, measured on a ten-point scale from complete dissatisfaction to complete satisfaction, was overwhelmingly positive: 98.5 percent of patients scored their experience at seven or higher, and only a single patient recorded the lowest possible score. For a procedure involving the percutaneous puncture of the liver, the placement of multiple catheters, and the delivery of a high radiation dose directly into malignant tissue, a zero rate of major complications in 74 patients is a result that demands attention.

The biological logic of the technique may partly explain why patients tolerate it so well. Unlike radiofrequency or microwave ablation, where heat generation within the liver can be genuinely painful and respiratory movement during the procedure can compromise both safety and effectiveness, the radiation delivered by an HDR iridium-192 source is itself painless. This, the authors note, potentially accounts for the absence of any significant association between tumor location and pain perception in their data. The trade-off is time and logistics: the procedure takes longer than thermal ablation because of the transfer to the radiation room and the delayed catheter removal, and it is precisely this duration and change of setting that makes conscious sedation arguably more practicable than general anesthesia, avoiding the overhead, risks, and resource demands of an anesthesiology team.

The broader context makes the finding timely. Minimally invasive tumor ablation has surged to an all-time high, driven in part by landmark randomized evidence that thermal ablation can match surgical resection for small colorectal liver metastases, and by emerging navigation techniques such as stereotactic puncture that are expanding what image-guided interventions can achieve. Previous work has shown that HDR brachytherapy achieves high rates of local tumor control without strict limitations on tumor size or location, including ablation of large and very large hepatocellular tumors and of lesions with portal vein tumor thrombosis. As the technique moves toward broader adoption, the anesthesia protocol becomes a genuine bottleneck or enabler: if every case requires general anesthesia, throughput is limited and costs rise, whereas a protocol that keeps the patient comfortable while awake can be integrated directly into the clinical routine of an interventional radiology unit.

The study’s authors are candid about its limitations. It was a single-center, monocentric investigation without a comparative arm, and it relied on patient interviews and structured questionnaires, which introduces the possibility of recall bias, since patient-reported data may be influenced by the timing of assessment. The absence of a general anesthesia comparison group means the study cannot definitively settle the ongoing global debate about the optimal anesthesia method for liver ablation, a debate that until now has drawn almost exclusively on hyperthermal ablation procedures rather than brachytherapy. Some studies have even suggested that general anesthesia might offer oncological advantages, although the authors argue that factors such as tumor location and size likely play a more significant role in outcomes than the sedation technique itself.

Even with those caveats, the conclusion is clear and consequential: CT-guided HDR brachytherapy under conscious sedation with analgesia, performed by interventional radiologists themselves, is safe, feasible, and well tolerated, with low subjective pain, near-universal patient satisfaction, and no major complications. Beyond the immediate clinical benefit for patients with liver malignancies, the finding carries a professional significance for the field. Delivering conscious sedation within the interventional radiology unit, without dependence on anesthesiology services, strengthens the specialty’s autonomy and supports its development as an independent clinical discipline. As the number of minimally invasive tumor ablations continues to climb across centers worldwide, this study suggests that the future of precision liver cancer radiation may be one in which patients remain awake, comfortable, and cared for by the same team that guides the catheters, plans the dose, and delivers the cure.

Subject of Research: Feasibility and safety of CT-guided high-dose-rate brachytherapy for liver tumors under conscious sedation with analgesia

Article Title: Feasibility and safety of CT guided high dose rate brachytherapy of liver tumors performed under conscious sedation with analgesia

Article References: Auer, T. A., Erforth, M. Z., Segger, L., Savic, L. J., Fleckenstein, F., Collettini, F., Fehrenbach, U., & Gebauer, B. (2025). Feasibility and safety of CT guided high dose rate brachytherapy of liver tumors performed under conscious sedation with analgesia. CVIR Oncology, 1(1), Article 26. https://doi.org/10.1007/s44343-025-00026-y

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00026-y

Keywords: brachytherapy, liver cancer, interventional radiology, conscious sedation, CT guidance, hepatocellular carcinoma, iridium-192, pain management, tumor ablation, radiation oncology, patient safety, minimally invasive therapy

Neuroblastoma is a cancer of the sympathetic nervous system that arises most often in the adrenal glands or along the spine, and it accounts for a disproportionate share of childhood cancer deaths. The girl at the center of this report carried one of the worst prognostic markers in the disease: amplification of the MYCN gene, a genetic signature associated with aggressive, treatment-resistant tumors. Her initial treatment followed the standard European induction protocol known as COJEC, a rapid cycle of cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide, followed by two courses of topotecan, vincristine, and doxorubicin. When doctors re-evaluated her disease, the news was grim. The primary tumor in her abdomen remained large and active, it pressed on critical blood vessels, and scans revealed widespread involvement of her bones and bone marrow, yielding a skeletal disease score of 45 on the SIOPEN scale used across European pediatric oncology centers.

What followed was a relentless escalation of therapy. Second-line chemotherapy with temozolomide and irinotecan, later combined with the anti-GD2 antibody dinutuximab beta, succeeded in clearing the metastatic disease from her bones and marrow. She then underwent consolidation with two rounds of radiometabolic therapy using iodine-131 labeled MIBG—a radioactive form of the same tracer molecule used to image neuroblastoma—each followed by reinfusion of her own stem cells, and finally high-dose chemotherapy with busulfan and melphalan supported by another stem-cell rescue. Yet when the dust settled, one enemy remained entrenched: a residual mass in her retroperitoneum, the space behind the abdominal organs, measuring 13.3 by 9.8 by 6.9 centimeters. The mass continued to light up on MIBG scans, proof that living neuroblastoma cells persisted within it, and it wrapped around the celiac artery and the right renal artery while compressing the inferior vena cava, the largest vein in the body.

This anatomical situation presented surgeons with an impossible calculus. Any attempt at resection risked catastrophic hemorrhage from vessels that the tumor had encased, and there was no guarantee that a complete removal could be achieved even at that price. A biopsy taken through the skin confirmed that the mass contained viable neuroblastoma tissue showing differentiating features, meaning the cells were still alive and capable of regrowth. It was at this impasse that a multidisciplinary tumor board—bringing together pediatric oncologists, surgeons, interventional radiologists, pathologists, and radiation therapists at Bambino Gesù Children’s Hospital in Rome—turned to a technique that had never before been applied to a child with this disease: percutaneous electrochemotherapy.

The principle behind electrochemotherapy is elegantly physical. Cell membranes, though thin, are formidable barriers that normally prevent many chemotherapy drugs from entering cells efficiently. When short, high-voltage electric pulses are applied across a tissue, they transiently reorganize the lipid bilayer of those membranes, opening nanoscale pores in a process called reversible electroporation. The pores allow drug molecules to flood into the cell interior, and because the pulses are calibrated carefully, the membranes reseal afterward and the cells survive—only to be killed by the chemotherapy they have now absorbed in quantities far beyond what ordinary exposure could achieve. The drugs most commonly paired with electroporation are bleomycin and cisplatin, both of which become dramatically more cytotoxic inside electroporated cells. In adults, the technique has earned validated roles against melanoma, sarcoma, and head and neck tumors, but pediatric experience has been almost nonexistent.

The Roman team tailored the procedure to the unique biology of neuroblastoma. Rather than administering cisplatin intravenously, they injected it directly into the tumor, a strategy designed to maximize drug concentration within the lesion while minimizing systemic side effects—a rational choice given that platinum compounds are among the drugs to which neuroblastoma is classically sensitive. Under general anesthesia, with the child positioned prone, three variable-geometry needle electrodes with an active length of three centimeters were inserted intercostally, between the ribs, using computed tomography and ultrasound guidance. The target was the most metabolically active portion of the mass, precisely the region where MIBG single-photon emission imaging had shown the greatest tracer uptake and where the tumor pressed hardest against the inferior vena cava. Once the electrodes bracketed the target, an 18-gauge coaxial biopsy was taken through the field, and four milligrams of cisplatin at a concentration of two milligrams per milliliter were injected through a Chiba needle. The Cliniporator VITAE device then delivered voltage pulses ranging from 900 to 1,700 volts, completing the session.

The technical choreography matters because electroporation is unforgiving of sloppy planning. The electric field must cover the entire tumor volume homogeneously; any region that falls between electrodes may receive sub-lethal exposure and survive as a seed of recurrence. This is why careful pre-treatment planning and meticulous electrode placement are considered the linchpins of the technique, particularly for large or irregularly shaped lesions like the one in this case. Encouragingly, the procedure itself was uneventful. No immediate or delayed complications occurred, post-procedure monitoring revealed nothing concerning, and the child was discharged in stable condition. The team notes that the approach is also repeatable, an important attribute for a disease where residual lesions sometimes require more than one local intervention.

The follow-up imaging tells the story in two snapshots. One month after the procedure, magnetic resonance imaging revealed a necrotic, liquefied area of 20 by 20 millimeters within the treated field—direct evidence that the electroporated cells had died on schedule, consistent with the six-to-eight-week window in which electrochemotherapy’s radiological effects typically become apparent. The child then completed her maintenance phase of treatment with cis-retinoic acid and dinutuximab beta without any complications. Twelve months after the procedure, computed tomography and MIBG imaging delivered the decisive verdict: the mass had shrunk to 9.2 by 8.9 by 9.4 centimeters, and, critically, no residual MIBG uptake could be detected anywhere in the treated area. The metabolically active component that had survived everything modern pediatric oncology could throw at it had been silenced.

Why does the disappearance of MIBG avidity matter so much? MIBG is a norepinephrine analog that is taken up specifically by neuroblastoma cells, so persistent tracer uptake is a molecular signature of living tumor. In neuroblastoma, residual primary disease that remains MIBG-avid after multimodal treatment is a well-established negative prognostic factor, strongly correlated with relapse and poor survival. The ability to selectively target and neutralize these metabolically active foci—without opening the abdomen, without thermal energy that could damage vessels and adjacent organs, and without adding systemic toxicity—addresses one of the most frustrating gaps in current therapy. Thermal ablation techniques such as radiofrequency ablation and cryoablation have been used in selected pediatric tumors, but they are hazardous near major vessels, which act as heat sinks and limit ablation margins, and near structures like the celiac artery that cannot tolerate thermal injury. Electrochemotherapy’s non-thermal mechanism sidesteps that constraint, and the authors note that its effects are applicable across tumor histologies, including tumors resistant to other modalities.

The caveats are as important as the promise. This is a single case, reported by the team of Giulia Cassanelli, Maria Antonietta De Ioris, and Gian Luigi Natali, and pediatric oncology is littered with promising one-patient results that failed to generalize. The authors themselves are careful, framing electrochemotherapy as a feasible local option for selected patients and calling for further evaluation within a multidisciplinary framework rather than declaring a new standard of care. Yet the signals here are hard to dismiss: a first-in-child application performed safely in one of the most anatomically hostile locations imaginable, durable local control of the exact tumor component that predicts relapse, and a treatment that can be repeated if needed. If larger studies confirm these findings, children with refractory neuroblastoma whose tumors are deemed inoperable may one day have an option that today they lack entirely—a minimally invasive, precisely targeted way to finish what chemotherapy, antibodies, and radiation started.

Subject of Research: Electrochemotherapy for residual MIBG-avid disease in refractory pediatric neuroblastoma

Article Title: Electrochemotherapy as a potential local treatment for residual MIBG-avid disease in refractory pediatric neuroblastoma: a case report

Article References: Cassanelli, G., De Ioris, M. A., & Natali, G. L. (2026). Electrochemotherapy as a potential local treatment for residual MIBG-avid disease in refractory pediatric neuroblastoma: a case report. CVIR Oncology, 2(1), Article 3. https://doi.org/10.1007/s44343-026-00032-8

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00032-8

Keywords: neuroblastoma, electrochemotherapy, electroporation, cisplatin, pediatric oncology, interventional radiology, MIBG imaging, tumor ablation, MYCN amplification, residual disease, case report, local therapy

The review synthesizes three decades of literature, spanning 1995 through early 2025, on five distinct ablation modalities applied to malignant solid tumors in patients aged 18 years or younger: radiofrequency ablation, cryoablation, microwave ablation, irreversible electroporation, and electrochemotherapy. Each works through a fundamentally different biophysical mechanism. Radiofrequency ablation, the oldest and most widely studied thermal technique, drives alternating electrical current through an electrode tip, generating resistive heat that coagulates tissue at temperatures above roughly 60 degrees Celsius. Cryoablation takes the opposite approach, cycling argon and helium gases through a probe to freeze and thaw tissue, rupturing cell membranes through ice-crystal formation and osmotic stress. Microwave ablation uses electromagnetic fields at around 915 MHz or 2.45 GHz to agitate water molecules, heating tissue faster and over larger volumes than radiofrequency energy while remaining less susceptible to the heat-sink effect created by nearby blood vessels, a phenomenon in which circulating blood carries thermal energy away from the treatment zone and leaves tumor cells at the margin viable.

The two nonthermal techniques in the review sidestep heat altogether. Irreversible electroporation delivers short, high-voltage electrical pulses that destabilize cell membranes, creating permanent nanoscale pores that trigger cell death while largely preserving the protein scaffolding of surrounding tissue, including blood vessels, nerves, and ducts. That tissue-sparing property makes it theoretically attractive near critical structures such as the liver hilum, though animal work has shown that cardiac-gated synchronization is needed to prevent ventricular arrhythmias when ablation occurs near the heart. Electrochemotherapy combines intravenous or intratumoral chemotherapy, typically bleomycin, with electrical pulses that transiently permeabilize cell membranes, dramatically increasing drug uptake inside tumor cells. A 2026 case report highlighted in the review describes electrochemotherapy as a potential local treatment for residual MIBG-avid disease in refractory pediatric neuroblastoma, illustrating how the technique may reach children whose disease resists conventional therapy.

Behind the technical catalog lies an epidemiological backdrop that gives the review its urgency. The authors report that hepatoblastoma, the most common malignant liver tumor of early childhood, has shown the steepest rising incidence among ablation-relevant solid tumors, with an annual percent change of +2.17 percent. Meanwhile, five-year survival for pediatric bone tumors and soft tissue sarcomas remains stuck near 60 percent, a figure that has improved only incrementally over decades. For children with relapsed or refractory disease, options narrow sharply, and this is precisely where ablation has carved out its clinical niche. The review is emphatic on one point: surgical resection and systemic chemotherapy remain the primary treatment for all malignant solid tumors discussed, and ablation is reserved for relapsed, refractory, or surgically limited scenarios, such as pulmonary metastases of osteosarcoma that cannot all be removed surgically, or recurrent liver tumors in a child who has already undergone hepatic resection.

The clinical evidence, however, is fragile. For malignant solid tumors, the review finds the literature limited to small retrospective series with heterogeneous populations and short follow-up, precluding any conclusions about survival benefit. A phase 1 pilot study of radiofrequency ablation for recurrent pediatric solid tumors published in Cancer in 2009 remains one of the few prospective efforts, and a 2014 systematic review in Pediatric Radiology, along with a 2020 meta-analysis of interventional radiology-guided procedures in pediatric solid tumors in the European Journal of Pediatric Surgery, both concluded that the pediatric literature consists largely of case reports and single-institution experiences. A 2022 series in Pediatric Blood & Cancer on percutaneous ablation of malignant and locally aggressive solid tumors in children added valuable multi-modality data but remained retrospective. The contrast with adult interventional oncology is stark: in adults, randomized trials and large registries have established ablation as standard care for selected hepatocellular carcinomas and other lesions, while pediatric practice continues to extrapolate from devices and evidence generated for grown bodies.

That extrapolation problem is more than academic. A 2023 study in Cardiovascular and Interventional Radiology asked pointedly whether there is really no kit for kids, quantifying how few high-volume interventional radiology devices carry manufacturer recommendations for pediatric use. Ablation probes are sized, powered, and shaped for adult anatomy; a probe designed to create a five-centimeter ablation zone in an adult liver may overshoot dangerously in the liver of a toddler. Pediatric operators must therefore adapt technique on the fly, adjusting power settings, overlapping smaller ablations, and relying on experience rather than validated device labeling. The same research group published a companion analysis in 2023 on cryoablation for bone and soft tissue lesions in pediatric patients, cataloguing complications and preventive measures, and a 2024 report describing a decade of cryoablation experience in extra-abdominal desmoid tumors in children and young adults, one of the larger single-center pediatric ablation experiences in the literature.

Imaging guidance is the quiet enabler of all these techniques, and its evolution matters as much as the energy sources themselves. Ultrasound offers real-time visualization without ionizing radiation, a decisive advantage in children, but struggles with deep or bone-encased targets. Computed tomography provides precise needle-path planning for lung and bone lesions, as demonstrated in the CT-guided thermal ablation of pulmonary osteosarcoma metastases reported in Annals of Surgical Oncology in 2016. Magnetic resonance guidance represents the frontier: MR thermometry allows operators to watch temperature maps build in real time, and MR-guided focused ultrasound surgery, which ablates through intact skin without any needle at all, has established clinical services for pediatric bone tumors such as osteoid osteoma, as outlined in 2016 guidelines for building such programs. Three-dimensional visualization systems have also been paired with microwave ablation for relapsed hepatoblastoma in a small pilot study, suggesting that fusion imaging and volumetric planning will increasingly define the pediatric standard of care.

What emerges from the review is a field at an inflection point. Clinical adoption is accelerating, device technology is improving, and the biophysical rationale for each modality is well understood, yet the pediatric evidence remains confined to small, retrospective, single-institution series with heterogeneous populations and short follow-up. The authors identify a coordinated multicenter registry with standardized survival endpoints as the most urgent unmet need in the field, a call that echoes the standardization of terminology and reporting criteria established for image-guided tumor ablation in the adult literature more than a decade ago. Without shared endpoints, pooled data, and honest complication reporting, pediatric ablation risks remaining a promising anecdote rather than an evidence-based option. The review also transparently notes that generative AI was used during manuscript preparation to cross-check the literature search and copy-edit, with all content reviewed and verified by the authors, a sign of how the field’s own scholarship is modernizing.

For families facing a relapsed osteosarcoma nodule in the lung, a recurrent hepatoblastoma after resection, or a refractory neuroblastoma mass wrapped around vital structures, image-guided ablation already offers something precious: a percutaneous option that can destroy tumor while preserving tissue, function, and future growth potential. The review’s message to the medical community is that the next decade must be spent proving, not merely practicing, that promise. With hepatoblastoma incidence climbing, survival for sarcomas plateauing near 60 percent, and devices still built for adults, the children who stand to benefit most from needle-based tumor destruction are precisely those whose evidence base is weakest. Turning scattered single-center experiences into a rigorous, multicenter evidence engine, the authors argue, is no longer optional. It is the prerequisite for making image-guided ablation a standard, trusted pillar of pediatric cancer care rather than a last resort practiced in the shadows of the operating room.

Subject of Research: Image-guided percutaneous ablation modalities for malignant solid tumors in children

Article Title: Image-guided ablation for pediatric malignant solid tumors: a review of modalities, evidence, and clinical applications

Article References: Shashi, K., Sabado, J., Chewning, R., Shahin, M., & Shaikh, R. (2026). Image-guided ablation for pediatric malignant solid tumors: a review of modalities, evidence, and clinical applications. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06781-1

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06781-1

Keywords: pediatric oncology, image-guided ablation, radiofrequency ablation, cryoablation, microwave ablation, irreversible electroporation, electrochemotherapy, hepatoblastoma, sarcoma, interventional radiology, Pediatric Radiology, tumor ablation

The research, led by Chih-Ying Huang and colleagues at Taipei Veterans General Hospital and National Yang Ming Chiao Tung University in Taiwan, set out to determine whether fully automated AI segmentation could extract meaningful three-dimensional volumetric features from routine pre-treatment CT scans and whether those features correlated with outcomes after cryoablation for renal cell carcinoma. Rather than asking radiologists to eyeball categorical scores, the team deployed two deep learning tools to do the measuring: TotalSegmentator, a robust open-source system capable of segmenting more than 100 anatomic structures in CT images, and a model developed for the 2023 Kidney and Tumor Segmentation Challenge (KiTS23). Both are built on the nnU-Net framework, a self-configuring deep learning architecture that has become a workhorse of modern biomedical image segmentation.

The technical workflow is deceptively simple. For each patient, the pre-treatment nephrographic-phase contrast-enhanced CT scan was fed into the segmentation pipeline, which generated masks for the kidneys, renal tumors, and renal cysts. Masks for the renal sinuses, the central fat-filled cavity of the kidney that houses the collecting system and major blood vessels, were produced through a geometry-based approach described in the study’s supplementary material. Once the masks were generated, the software extracted a series of quantitative 3D features: tumor volume, an automated RENAL nephrometry score, the minimum distance between tumor and renal sinus, and a novel metric called tumor-renal sinus contact area, which quantifies the surface area over which the tumor directly abuts the renal sinus. On a GPU-accelerated workstation, the entire process took approximately five minutes per case, with an additional five minutes when manual correction was needed.

That manual correction proved to be the exception rather than the rule. Of the 116 patients in the study, only 16 required any adjustment to the automated masks, and most of those involved tumors lying adjacent to renal cysts or cases in which the algorithm failed to identify the tumor at all. No case required complete re-segmentation. This level of automation matters because conventional nephrometry scores suffer from well-documented interobserver variability. The R component of the RENAL score, for example, is measured on orthogonal planes and may not reflect the true maximal three-dimensional extent of a tumor, while the exophytic and location components have shown low perfect agreement among human readers. Continuous volumetric features extracted by software sidestep both problems, offering objective, reproducible numbers that capture anatomy in its full spatial complexity.

The study cohort consisted of 116 patients who underwent CT-guided percutaneous cryoablation for renal lesions at a single center between October 2009 and December 2024. The group comprised 85 men and 31 women with a mean age of 70.7 years, and the mean follow-up duration was 2.8 years. The mean tumor volume was 15.1 milliliters and the mean tumor diameter was 3.6 centimeters, consistent with the small, early-stage lesions for which ablation is typically recommended. Clear cell renal cell carcinoma was the most common histologic subtype, accounting for 64.7 percent of tumors. Notably, all cryoablation procedures throughout the fifteen-year inclusion window were performed by a single operator, which the authors suggest may have reduced variability related to procedural technique even as practice patterns evolved.

The clinical outcomes were assessed using standardized definitions from the International Working Group on Image-Guided Tumor Ablation and the SIO and DATECAN consensus guidelines. At the first post-ablation follow-up, 94 percent of patients achieved complete ablation, while 6 percent had residual unablated tumor requiring repeat cryoablation. Among those with complete initial ablation, 8 patients, or 6.9 percent of the cohort, later developed local tumor progression at the ablation margin. One patient with persistent tumor after re-ablation was ultimately found to have suspected venous invasion and a new lesion in the same kidney, requiring systemic therapy. To capture both early failure and later progression, the researchers defined a composite endpoint of local tumor control failure, combining residual unablated tumor and local tumor progression.

The statistical results pointed emphatically toward one feature. In univariable logistic regression, tumor volume, the RENAL nephrometry score, its R component, and tumor-renal sinus contact area were all significantly associated with local tumor control failure. But in a deliberately parsimonious multivariable model, limited by only 15 outcome events and bolstered by bootstrap resampling with 1,000 iterations to confirm coefficient stability, only tumor-renal sinus contact area remained independently predictive, with an odds ratio of 1.379 and a p-value of 0.002. The authors derived a composite risk score, calculated as 0.321 times the tumor-renal sinus contact area plus 0.023 times the tumor volume. In receiver operating characteristic analysis, this score achieved an area under the curve of 0.765 for predicting local tumor control failure, numerically higher than the 0.664 achieved by the RENAL nephrometry score, although the difference did not reach statistical significance on the DeLong test. With an optimal cutoff of 1.51, the score yielded a sensitivity of 67 percent and a specificity of 86 percent.

Two representative cases illustrate the score’s clinical texture. A 65-year-old man with biopsy-proven clear cell renal cell carcinoma had a 21.3-milliliter tumor with a tumor-renal sinus contact area of just 0.31 square centimeters, producing a risk score of 0.59, well below the cutoff. He underwent cryoablation and remained stable on follow-up imaging for more than four years. By contrast, a 91-year-old man with a similarly sized tumor of 25.2 milliliters but a contact area of 9.23 square centimeters scored 3.54, far above the threshold, and developed local tumor progression just nine months after treatment. In the Cox proportional hazards analysis, larger tumor-renal sinus contact area was also significantly associated with local tumor progression among patients who had achieved complete initial ablation, with a hazard ratio of 1.255 and a p-value of 0.026.

Why should contact with the renal sinus matter so much? The authors offer a biologically plausible but unproven explanation: the renal sinus contains major blood vessels whose continuous blood flow can dissipate cold energy from the ablation zone, a phenomenon known as the cold-sink effect. Tumors with extensive contact along the tumor-sinus interface may therefore be more susceptible to incomplete freezing, and indeed, viable tumor foci identified on follow-up imaging in this cohort were frequently located adjacent to the renal sinus. The researchers caution that this mechanism remains a hypothesis, since the study did not directly evaluate renal sinus vascular anatomy, tissue perfusion, intraprocedural temperature distribution, or ablation margin adequacy. Even so, the finding suggests that automated segmentation can capture an anatomically meaningful feature that is nearly impossible to quantify visually, information that existing categorical scoring systems simply do not encode.

The authors are careful to frame their conclusions as exploratory. The study was retrospective and single-center, the number of outcome events was small, the AI segmentation tools have not yet been formally validated across institutions and imaging protocols, and the composite risk score has not undergone external validation. Its discriminative performance was only moderate, and its incremental value over conventional predictors should be interpreted cautiously. Still, the implications are tantalizing. An objective, automated risk score generated in minutes from an existing CT scan could help clinicians identify anatomically challenging tumors, guide patient selection between ablation and surgery, and tailor surveillance intensity, with higher-risk patients potentially benefiting from closer imaging follow-up. Future work, the authors suggest, may extend the approach to segment renal vessels and ablation zones, register pre-treatment and intraprocedural images, and quantitatively assess ablation margins, bringing the field closer to a fully computational framework for predicting and ultimately preventing local treatment failure in kidney cancer.

Subject of Research: AI-based automated segmentation-derived 3D volumetric imaging features and outcomes after cryoablation for renal cell carcinoma

Article Title: Association between AI-based automated segmentation-derived 3D volumetric imaging features and outcomes after cryoablation for renal cell carcinoma

Article References: Huang, C.-Y., Hong, J.-A., Chang, N.-W., Li, C.-C., Liu, C.-A., & Shen, S.-H. (2026). Association between AI-based automated segmentation-derived 3D volumetric imaging features and outcomes after cryoablation for renal cell carcinoma. CVIR Oncology, 2(1), Article 24. https://doi.org/10.1007/s44343-026-00053-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00053-3

Keywords: renal cell carcinoma, cryoablation, artificial intelligence, automated segmentation, 3D volumetric imaging, tumor-renal sinus contact area, RENAL nephrometry score, tumor ablation, risk score, kidney cancer, radiology, predictive modeling

In current practice, the ice ball created by a cryoablation probe is a central visual guide. Imaging can show the approximate volume of frozen tissue, allowing operators to position applicators and judge whether the tumor is covered. Yet the outer boundary of an ice ball does not necessarily reveal the distribution of temperatures inside it. The temperatures commonly used as lethal benchmarks, around −20 °C to −40 °C, cannot be directly visualized in routine treatment images. As power is reduced to prevent the ice from reaching a vulnerable structure, the overall ice ball may remain similar in size while its colder internal isotherms contract. The result can be a larger marginal zone, spanning temperatures from roughly 0 °C to the lethal threshold, where cells experience sublethal stress and may recover. The CCD model is designed to address that uncertainty by asking not simply whether a location lies inside the ice ball, but whether it has accumulated sufficient time at or below the cell type’s lethal threshold.

The researchers developed the model through a systematic review conducted under PRISMA 2020 guidelines. Searches of PubMed, Embase and Web of Science, covering the available literature through March 2025, identified studies reporting the effects of freeze duration, cell-specific lethal thresholds, lethal isotherm ratios or outcomes associated with particular treatment protocols. Two reviewers independently screened the records, and 43 studies met the inclusion criteria. The evidence base comprised 24 in vitro studies, nine in vivo studies, seven clinical studies and three reviews. CCD was defined as the total time tissue remains at or below its cell-type-specific lethal threshold across all freeze cycles, excluding the intervals used for thawing. For modeling purposes, a point was considered lethally dosed when its accumulated exposure corresponded to a probability of at least 80 percent cell death. The authors describe that level as a conservative lower bound for anatomically constrained treatments, while noting that procedures performed with curative intent and unconstrained margins may require higher targets.

The model’s duration component was calibrated using data from an in vitro study of the transition zone. In that source study, extending exposure from 60 seconds to 120 seconds increased marginal-zone cell death from 42.5 percent to 84.8 percent. The researchers fitted those two points to a logistic curve, using a growth parameter of 0.0538 and a midpoint of 86 seconds. The resulting calculation estimated that a single freeze cycle would need at least 120 seconds to reach the model’s 80-percent cell-death target. Repeating the freeze changed the estimated requirement because processes such as ice recrystallization and incomplete membrane repair during passive thaw can amplify injury between cycles. Under the model’s conservative amplification assumption, the minimum exposure fell to 50 seconds per cycle for a double-cycle protocol and 31 seconds per cycle for a triple-cycle protocol. These values describe effective dose targets in the model, not universally established treatment instructions.

The review also examined how treatment power and ice-ball size affect the spatial distribution of cold. The analysis modeled three cryoablation systems, four ice-ball sizes ranging from 25 to 40 millimeters and power settings between 40 and 100 percent. The calculations assumed that the lethal zone shrinks proportionally as power decreases, although the authors emphasized that this linear relationship has not been fully validated. At 40 percent power, the −20 °C isotherm contracted to approximately 25 to 30 percent of the total ice-ball width. This contraction expanded the marginal zone by as much as 3.9-fold. A visible ice ball could therefore occupy the intended treatment volume while containing a much smaller region exposed to temperatures expected to cause direct lethal injury. Sensitivity analyses using more conservative and more optimistic scaling assumptions changed CCD targets by about 15 to 25 percent, highlighting the uncertainty surrounding the geometry calculations.

The predicted consequences differed according to how resistant the target tissue was to cold. For cold-sensitive tissues, the model found that double-cycle protocols could maintain an adequate cumulative dose across all tested power levels, with estimated exposures of 50 to 125 seconds per cycle. For cold-resistant phenotypes, which may require temperatures near −40 °C for direct lethal injury, most configurations required escalation to triple-cycle protocols, multi-probe overlap or reliance on additional mechanisms of tissue destruction. The analysis found that double cycling increased renal cell lethality from 22 to 62 percent at −10 °C and from 63 to 89 percent at −15 °C in the underlying evidence. It also noted that a meta-analysis involving 786 patients had associated longer freeze duration with better local tumor control. That clinical association supports the importance of time, but it does not by itself prove that the CCD model accurately predicts outcomes for individual patients.

The model offers a practical way to interpret multi-cycle treatment. Under its proposed logic, the first cycle can establish the desired treatment geometry, while later cycles deliver additional biological dose without necessarily expanding the ice ball beyond an anatomical boundary. The source article illustrates this concept with a palliative cryoablation procedure for a 25-millimeter ovarian metastasis near the left psoas, between the L2 and L3 nerve roots. A single applicator was operated at 30 to 40 percent power to constrain the ice ball, and a triple-cycle protocol with passive thawing was used to compensate for the reduced internal isotherms. The first cycle lasted five minutes at 30 percent power, followed by seven minutes at 40 percent and five minutes at 30 percent. The reported procedure produced no observed nerve damage during follow-up. The example demonstrates how the model could rationalize repeated freezing, although one case cannot establish efficacy or safety for broader clinical use.

Important biological limitations remain. Measurements derived from cultured cells cannot be transferred directly to living tumors, where blood flow can carry heat into the treatment margin and shorten the effective duration of cold exposure. This heat-sink effect may be partly offset in later cycles if the first freeze damages blood vessels and reduces local perfusion. Cell type, tissue composition, tumor architecture and temperature history can also influence the response. CCD currently counts time below a fixed threshold rather than assigning a continuous weight to different subzero temperatures. In that respect, it is simpler than the cumulative equivalent minutes at 43 °C model used for hyperthermia, which weights time and temperature continuously. The present calibration relies on only two duration points, the validated duration range is limited to 60 to 120 seconds, and the assumed relationship between power reduction and isotherm contraction remains unconfirmed. The authors therefore present CCD as a structured, testable hypothesis. Prospective studies combining real-time thermometry with volumetric treatment outcomes will be needed before it can guide routine care. If those studies confirm the predictions, cumulative cold dose could give interventional radiologists a quantitative language for choosing freeze duration, cycle number and probe arrangement—especially when tumor control must be balanced against the safety of nearby healthy tissue.
A further implication of the proposed framework is that treatment adequacy would have both spatial and volumetric dimensions. It would not be enough for a few sampled locations to exceed a CCD threshold; the threshold would need to be achieved across a prespecified fraction of the treatment volume. This distinction matters because temperature gradients are steep near the ice-ball margin, and a treatment could contain highly dosed central tissue alongside underdosed peripheral tissue. In principle, thermometry or validated thermal modeling could generate a three-dimensional map of accumulated dose rather than relying on a single visible boundary.

The model also separates the size of the frozen region from its spatial efficiency. The lethal isotherm ratio, or LIR, estimates the proportion of ice-ball width occupied by a selected lethal isotherm. In the reviewed comparisons, the liquid-nitrogen system had the highest reported ratios for a 25-millimeter ice ball, including an approximately 82.6% ratio at −20 °C and 63.3% at −40 °C. By contrast, a larger clustered configuration could produce a greater absolute lethal-zone width while having lower spatial efficiency. These measures therefore answer different planning questions: whether a system can reach a required temperature, how much of the target can be exposed to it, and whether additional cycles or overlapping probes are needed.

CCD may ultimately support adaptive treatment rather than a fixed protocol selected before the procedure. A clinician could begin with a geometry-limited freeze, use measured temperatures or system-specific isotherm estimates to identify underdosed regions, and then adjust cycle duration, power or probe overlap. Such an approach would require reliable calibration for each device and tissue context, because the review combined heterogeneous experimental and clinical evidence. The authors also tested inter-cycle amplification across a broad range and used the conservative end for their principal recommendations, underscoring that the benefit attributed to repeated freezing is not a single settled biological constant. Prospective validation would need to compare predicted dose maps with biopsy, imaging, local-control and toxicity outcomes while accounting for blood flow and temperature measurement error.

Subject of Research: Cumulative cold-dose modeling for cryoablation treatment planning

Article Title: A cumulative cold dosimetry model for cryoablation: from geometry to dose-time planning

Article References: Cornelis, F. H., Cornelis, A. A., & Solomon, S. B. (2026). A cumulative cold dosimetry model for cryoablation: from geometry to dose-time planning. CVIR Oncology, 2(1), Article 20. https://doi.org/10.1007/s44343-026-00058-y

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00058-y

Keywords: cryoablation, cumulative cold dose, cancer treatment, dosimetry, thermal isotherms, cell death, interventional radiology, tumor ablation, cumulative, cold, model, geometry